Enterprise Value

12.17B

Cash

595.7M

Avg Qtr Burn

-143.5M

Short % of Float

8.72%

Insider Ownership

1.01%

Institutional Own.

95.35%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
ARIKAYCE (Amikacin Liposome Inhalation Suspension) Details
Mycobacterium avium complex lung disease, Nontuberculous mycobacterial lung disease

Approved

Update

ARIKAYCE (Amikacin Liposome Inhalation Suspension) Details
Mycobacterium avium complex lung disease, Nontuberculous mycobacterial lung disease

Phase 3

Data readout

Brensocatib (DPP1 inhibitor) Details
Non-Cystic Fibrosis Bronchiectasis

Phase 3

Update

TPIP (Treprostinil Palmitil Inhalation Powder) Details
Pulmonary hypertension, Interstitial lung disease

Phase 3

Initiation

Phase 2

Data readout

Phase 2

Data readout

Phase 2

Update